Details for Patent: 9,127,276
✉ Email this page to a colleague
Which drugs does patent 9,127,276 protect, and when does it expire?
Patent 9,127,276 protects DAWNZERA (AUTOINJECTOR), TRYNGOLZA (AUTOINJECTOR), WAINUA, and WAINUA (AUTOINJECTOR), and is included in three NDAs.
This patent has two hundred and sixty-one patent family members in forty countries.
Summary for Patent: 9,127,276
| Title: | Conjugated antisense compounds and their use |
| Abstract: | Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine. |
| Inventor(s): | Thazha P. Prakash, Punit P. Seth, Eric E. Swayze |
| Assignee: | Ionis Pharmaceuticals Inc |
| Application Number: | US14/267,842 |
|
Patent Claim Types: see list of patent claims | Compound; |
Drugs Protected by US Patent 9,127,276
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ionis Pharms Inc | DAWNZERA (AUTOINJECTOR) | donidalorsen sodium | SOLUTION;SUBCUTANEOUS | 219407-001 | Aug 21, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Ionis Pharms Inc | TRYNGOLZA (AUTOINJECTOR) | olezarsen sodium | SOLUTION;SUBCUTANEOUS | 218614-002 | Jun 24, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Ionis Pharms Inc | TRYNGOLZA (AUTOINJECTOR) | olezarsen sodium | SOLUTION;SUBCUTANEOUS | 218614-001 | Dec 19, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Astrazeneca Ab | WAINUA | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-002 | Apr 15, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,127,276
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3524680 | ⤷ Start Trial | CA 2025 00027 | Denmark | ⤷ Start Trial |
| European Patent Office | 3524680 | ⤷ Start Trial | C20250028 | Finland | ⤷ Start Trial |
| European Patent Office | 3524680 | ⤷ Start Trial | 301341 | Netherlands | ⤷ Start Trial |
| European Patent Office | 3524680 | ⤷ Start Trial | 122025000044 | Germany | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
